Clinical Trial Update: Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated immunogenicity and safety of three dengue vaccine formulations in healthy adults aged 18-45 in the US; results posted after c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Dengue vaccine formulations (three)

Snippet

Sponsor: Sanofi | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-06-11